Building the Future of
Israeli Biotech

About

Israel Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israeli-based biotech companies.

Based in Rehovot, Israel’s main Biotech hub, we invest exclusively in Biotech companies developing drugs. We don’t just invest in promising companies – we have the ability, experience and network required to identify the best opportunities and partner with our portfolio companies to help them go the distance. The biotechnology industry in Israel is growing with enormous potential and we are determined to realize its full potential and real value.

Strategy

“We invest in Israeli and Israeli related biotechnology and pharmaceutical companies with exceptional technologies or product opportunities based on strong scientific rationale and commercial potential.”

Our key asset is a unique team of nearly 30 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support.

We provide our portfolio companies with the necessary resources for long-term sustainable growth. We provide them with access to network, executive talent, strategic, operational, and business development resources.

This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities.

Portfolio

Team

David Sidransky, MD​

Co-Founder and Managing Partner

Co-Founder and Managing Partner of Israel Biotech Fund. Dr. Sidransky is a renowned oncologist, research scientist and Professor of Oncology and Cellular & Molecular Medicine at John Hopkins University and Hospital. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals, (NASDAQ: ONCM), a genetic testing company that was sold to Gene Logic in 1998, and Response Genetics (NASDAQ: RGDX), a developer of markers for cancer therapy.
https://www.linkedin.com/in/david-sidransky-0095253

Yuval Cabilly, Ph.D.

Co-Founder and Managing Partner

Co-Founder and Managing Partner of Israel Biotech Fund. Dr. Cabilly has vast experience in identifying, funding and engaging in business development activities of Israeli biotech companies. Dr. Cabilly received his PhD in molecular cell biology from Tel Aviv University, where he focused his research on a neurodegenerative disease, and several of his articles have been published in well-known scientific journals.
https://www.linkedin.com/in/yuval-cabilly-4a105b50

Ido Zairi

Co-Founder and Managing Partner

Co-Founder and Managing Partner of Israel Biotech Fund. Mr. Zairi is a founder and Managing Director of the Mendham Investment Group (MIG). He is a former Managing Director and Head of Risk Management at Jefferies & Company, where he was responsible for risk management of over $15 billion in assets. Prior to that he was the Head of Risk Management at Knight Trading Group and an option trader on the CBOE. Mr. Zairi holds a B.A in economics from the Hebrew University of Jerusalem.
https://www.linkedin.com/in/ido-zairi-b980884

Sarit Steinberg, Adv.

Partner

Partner & General Counsel at Israel Biotech Fund. Sarit Steinberg is a specialized executive in corporate operations and legal affairs, with a proven track record in cross-border mergers & acquisitions and commercial transactions. She has years of experience representing companies as in house counsel and as an associate in a law firm in the high-tech and biotech sectors. Sarit completed her higher-education in London, England (Queen Mary College, LL.B. (Hons.), London School of Economics, LL.M. Corporate Law (Hons. Merit).
https://www.linkedin.com/in/sarit-steinberg-9b26a934/

Ariel Kamsler, Ph.D.

Associate

Associate at Israel Biotech Fund. Ariel Kamsler brings years of experience in drug development and evaluation. Ariel worked at Teva, where he was a formulation researcher and project manager responsible for new product evaluations. Ariel led the formulation lab at CTS pharmaceutical industries and was later responsible for clinical operations at RDD Pharma. Ariel holds a Ph.D. in Neurobiology from the Weizmann Institute and his postdoctoral training was carried out at MIT.
https://www.linkedin.com/in/ariel-kamsler-a1b8b62

Mordechai Applebaum, Ph.D., MA

Analyst

Analyst at Israel Biotech Fund. Mordechai has extensive experience developing biologic treatment, with a focus on immuno-oncology, from Enlivex Therapeutics and Vaxil Biotherapeutics. Mordechai has a PhD in Medical Sciences and an MA cum laude in Philosophy from The Hebrew University.
https://www.linkedin.com/in/mordechai-applebaum/

Elaine Adler, PhD

Analyst

Dr. Adler brings extensive experience in drug development and evaluation. Prior to joining Israel Biotech Fund, Elaine worked as a Scientist, Project Leader and Team Leader responsible for non clinical pharmacology development at TEVA. Elaine holds a Ph.D. in Physiology from Monash University, Australia. Elaine completed her postdoctoral training in Neurobiology at the Weizmann Institute of Science under the supervision of Professor Alon Chen. In support of her work at the Weizmann Institute, Elaine received a National Network of Excellence fellowship from TEVA.

Avi Shachar, CPA

Controller

Avi has extensive experience with high-tech companies, startups and venture capital funds. Avi performed audit in accordance with U.S. GAAP, Israeli GAAP and IFRS. Prior to joining Israel Biotech Fund, Avi was an Audit Senior Manager at Deloitte specializing in Israeli & global high-tech companies and venture capital funds. Avi has a B.A. in accounting and business, and LL.B and is a Certified Public Accountant (CPA) in Israel.

Bosmat Filosof​

Executive Assistant

Bosmat is the Executive Assistant at Israel Biotech Fund working with all Managing Partners as well as the other team members of the Fund. Prior to working at Israel Biotech Fund, Bosmat worked for many years as an operations manager.

Venture Advisors

Sol Barer, Ph.D.

Chairman, Teva;
Former Chairman and CEO, Celgene

Chairman, Teva. Former Chairman and CEO of Celgene (NASDAQ: CELG), which under Dr. Barer’s leadership, developed into one of the world’s largest independent Biotech company. Dr. Barer currently serves on the board of several Biotech companies including TEVA.

Jeff Kindler

Former Chairman and CEO, Pfizer; CEO of Centrexion Therapeutics

CEO of Centrexion Therapeutics Corp. Former Chairman and CEO of Pfizer (NYSE: PFE), the world’s largest, research-based biopharmaceutical company. Mr. Kindler served as a board member of the Federal Reserve Bank of New York. He is currently the CEO of Centrexion and serves on the board of several public and private companies.
https://www.linkedin.com/in/jeffrey-b-kindler-a304b136

Harlan Weisman, MD

Former J&J Company Group Chairman, Pharmaceutical R&D; CSO & CTO, Medical Devices

Former J&J executive positions including Company Group Chairman, Pharmaceutical R&D and Chief Science and Technology Officer, Medical Devices. Managing Director of And-One Consulting. Dr. Weisman served in senior positions at J&J and as Chairman and CEO of Coronado Biosciences. He is currently Executive Chairman, 3D Bio, on the Board of Governors of the Patient-Centered Outcomes Research Institute (PCORI), the Board of Directors of ControlRad Systems, and on advisory committees to the Johns Hopkins University Institute for Basic Biomedical Sciences and BioMotiv, a biotech accelerator company.
https://www.linkedin.com/in/harlan-weisman-0339877

Robert Spiegel, MD

Former Chief Medical Officer, Schering-Plough

Former Chief Medical Officer of Schering-Plough and Senior Vice President of the Schering-Plough Research Institute, where he was involved in the filing of over 30 new drug applications. Dr. Spiegel serves on the board of a number of public, private and non-profit companies and is the Chief Medical Officer of PTC Therapeutics.
https://www.linkedin.com/profile/view?id=AAkAAAGJkA4BRMlxJkcLjBd-VRXkUp5vAJV05Y4&authType=NAME_SEARCH&authToken=CjDc&locale=en_US&trk=tyah&trkInfo=clickedVertical%3Amynetwork%2CclickedEntityId%3A25792526%2CauthType%3ANAME_SEARCH%2Cidx%3A1-1-1%2CtarId%3A1448285734635%2Ctas%3Arobert%20spiegel

David J. Shulkin, MD

The Ninth Secretary of the US Department of Veterans Affairs

The Honorable Dr. David J. Shulkin was the ninth Secretary of the US Department of Veterans Affairs. Nominated by President Trump to serve in his Cabinet, Secretary Shulkin was confirmed by the US Senate by a vote of 100-0. Secretary Shulkin previously served as Under Secretary for Health having been appointed by President Obama and confirmed unanimously by the US Senate. As Secretary, Dr. Shulkin represented the 21 million American veterans and was responsible for the nation’s largest integrated health care system with over 1,200 sites of care, serving over 9 million Veterans. Prior to coming to VA, Secretary Shulkin was a widely respected healthcare executive having served as chief executive of leading hospitals and health systems including Beth Israel in New York City and Morristown Medical Center in Northern NJ. Over his career Secretary Shulkin has been named as one of the Top 100 Physician Leaders of Hospitals and Health Systems by Becker’s Hospital Review and one of the “50 Most Influential Physician Executives in the Country” by Modern Healthcare and Modern Physician. He has also previously been named, “One Hundred Most Influential People in American Healthcare” by Modern Healthcare.
https://www.linkedin.com/in/davidshulkin/

Jerome Zeldis, MD, PhD

Executive Chair, ViralClear Pharmaceuticals

Executive Chair of ViralClear Pharmaceuticals, former President of Clinical Research and Regulatory and Chief Medical Officer of Sorrento Therapeutics. Dr. Zeldis was CEO of Celgene Global Health and Chief Medical Officer of Celgene Corporation. Prior to that he was Celgene’s Senior Vice President of Clinical Research and Medical Affairs and has been at Celgene since 1997. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. He has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, PTC Corporation, Soligenix, Trek Therapeutics and Metastat. He has published 123 peer reviewed articles and 44 US patents.
https://www.linkedin.com/in/jerome-m-d-ph-d-zeldis-030b5410/

Eddy Shalev

Founder & Managing Partner, Genesis Partners

Founder & Managing Partner of Genesis Partners. Eddy is a founding leader of Israel’s venture capital industry. Since the beginning of Israel’s VC industry, Eddy has focused on private-equity investments in the high-tech sector, and has played a key role in several high-profile success stories.
https://www.linkedin.com/in/eddy-shalev-21064b9a

Murray A. Goldberg

Director, Teva;
Former CFO, Regeneron

Murray A. Goldberg has financial and operational experience at leading global pharmaceutical companies. Murray served as Senior Vice President-Administration and Chief Financial Officer of Regeneron Pharmaceuticals (NASDAQ:REGN), Chief Financial Officer, Treasurer & VP-Finance of PharmaGenics, Inc., and as a Managing Director-Structured Finance Group of The Chase Manhattan Bank NA. He currently serves as a director at Teva Pharmaceutical (NASDAQ:TEVA) and at Aerie Pharmaceuticals (NASDAQ:AERI). Murray received his undergraduate degree from New York University, a graduate degree from the London School of Economics & Political Science, and an MBA from the University of Chicago.

Steven Nichtberger, MD

Former Head of Marketing, Merck

Co-founder, Chairman, & CEO of Cabaletta Bio. Former Head of Marketing, Merck. A serial entrepreneur with 20 years of healthcare and industry experience focused on developing and commercializing breakthrough medical advances. Dr. Nichtberger is an Adjunct Professor at Wharton School.
https://www.linkedin.com/in/steven-nichtberger-md-78a5b48

Edward C. Saltzman

Executive Chairman, Cello Health BioConsulting

Executive Chairman, Cello Health BioConsulting, formerly, Defined Health. Head, Biotech Strategy, Lumanity, Board member, Nurix Therapeutics. Ed has more than 25 years of experience consulting to pharma, biotech, specialty pharma and investors and possesses a vast knowledge of the pharmaceutical and biotechnology industry.
https://www.linkedin.com/in/ed-saltzman-4b125113/

Michael G. Bator

Partner, Quartz Advisory; Former CFO, Trek Therapeutics

Partner, Quartz Advisory; Former CFO, Trek Therapeutics. Mr. Bator is a seasoned consultant and investor with 28 years of experience primarily focused on the life sciences and healthcare industries, including Medical Technology, Pharmaceuticals, HCIT and Services. He has been a Managing Director at Jennison Associates for 14 years where he has been a successful Equity Research Analyst and investor in all areas of healthcare both long and short.
https://www.linkedin.com/in/michael-g-bator-02899b

Richard Brudnick

Chief Business Officer, Codiak BioSciences

Chief Business Officer, Codiak BioSciences. Prior to joining Codiak, Mr. Brudnick was EVP of Business Development and Alliance Management at Bioverativ, Inc., a company he helped found in 2016. Prior to Bioverativ’s acquisition by Sanofi in March 2018, Mr. Brudnick successfully led business development efforts to build a significant pipeline in rare blood disorders including an acquisition the acquisition of True North Therapeutics. Mr. Brudnick joined Bioverativ at its spin-off from Biogen where, over the course of nearly 15 years, he initiated, led and completed transactions that now include many of the company’s marketed products and late-stage pipeline programs, including Tecfidera, Spinraza, its biosimilars joint venture with Samsung and its late stage Alzheimer’s programs partnered with Eisai. Mr. Brudnick also was CEO of a regional pharmaceutical distribution business, which he sold to a strategic buyer, co-founded two companies, and was a strategy consultant at Bain & Company
https://www.linkedin.com/in/richard-brudnick-8627246/

Ron Bentsur, MBA

Former CEO, UroGen Pharma; Former CEO, Keryx Biopharmaceuticals

Former CEO of UroGen Pharma (NASDAQ: URGN), former CEO of Keryx Biopharmaceuticals (NASDAQ: KERX) leading the company to the FDA approval of AuryxiaTM, former Chief Executive Officer of XTL Biopharmaceuticals.

Stanley Bernard, MD, MBA

President, Bernard Associates

President, Bernard Associates, the leading global competition consulting firm for the pharmaceutical and health care industries. Dr. Bernard is internationally recognized as a pharmaceutical and healthcare industry competition consultant, speaker and author.
https://www.linkedin.com/in/stanbernardmdmba

Jeffrey Berkowitz

CEO, Real Endpoints

CEO, Real Endpoints. Jeff is one of the rare executives whose career has spanned most key verticals in global healthcare with executive committee and other senior roles at UnitedHealth Group, Walgreens Boots Alliance and Merck. Prior to Real Endpoints, Jeff served as an Executive Vice President of UnitedHealth Group/Optum where he lead Optum’s International division as CEO while also driving key strategic initiatives within Optum’s pharmacy benefits management division. Prior to joining UnitedHealth Group/Optum in 2016, Jeff served at the Walgreens Boots Alliance, Inc. as President of Pharma and Global Market Access. Berkowitz serves on the board of directors of Lundbeck, Esperion Therapeutics and Infinity Pharmaceuticals, Inc. He also serves on the boards of the privately held ZappRx and Braeburn. Berkowitz also serves on the board of the non-profit, Project Explorer and served on the Board of Directors of the Swiss-American Chamber of Commerce.
https://www.linkedin.com/in/jeff-berkowitz-5635897/

Joshua B. Barer

Co-Founder, Hibiscus BioVentures

Josh is also CEO of Hibiscus Capital Management, Managing Partner at Barer & Son Capital and serves as a Director at Asclepix Therapeutics and several non-profits focused on interfaith work and economic development. Josh formerly worked with Trout Capital and the Maxim Group Venture Capital Division and is a former Board Observer of NexImmune (NEXI).
https://www.linkedin.com/in/joshua-barer-9437982b

Jesse M. Cedarbaum MD

Founder and Head, Coeruleus Clinical Sciences

Dr. Cedarbaum obtained his medical degree from Yale Medical School, where he is currently Professor (Adjunct) of Psychiatry. Dr. Cedarbaum led the Parkinson and Movement Disorders program at Burke Rehabilitation Center and the New York Hospital. Dr. Cedarbaum then joined Regeneron, where he led the establishment of the clinical development function and served as Program Director and later Vice President of Clinical Affairs. He subsequently held positions at Elan, Cytokinetics, and Bristol-Myers Squib and most recently as Sr. Distinguished Investigator at Biogen, leading a team focused on development of novel therapeutics for Parkinson’s disease and Movement Disorders. Dr. Cedarbaum has authored or co-authored over 100 peer-reviewed scientific publications, most in the area of neurotherapeutics.
https://https://www.linkedin.com/in/jesse-cedarbaum-4230327/

Andrew J. Einhorn

CFO, Osmotica Pharmaceutical; Former CFO, Edge Therapeutics

CFO, Osmotica Pharmaceutical; Former CFO, Edge Therapeutics; Mr. Einhorn is a Financial Executive & Entrepreneur with more than 12 years of experience in the pharmaceutical industry having been a co-founder and Chief Financial officer of several pharmaceutical and biotech companies. He also has more than 20 years of experience as an investment banker working extensively in corporate finance, capital markets and financial analysis.
https://www.linkedin.com/in/andrew-einhorn-34b9667

Jonathan Fassberg

Co-CEO, The Solebury Trout Group

Co-CEO, The Solebury Trout Group, a leading investor relations firm in the life sciences industry, Trout has served over 250 public and private companies from its six offices around the world. Trout’s clients also had challenges accessing capital, leading Mr. Fassberg to start Trout Group’s sister company, Trout Capital LLC, in 2004 to assist clients in a financial advisory role.
https://www.linkedin.com/in/jonathan-fassberg-762aaa5

Stanley B. Fiel, MD

Professor of Medicine, Sidney Kimmel Medical College; Thomas Jefferson Uni

Dr. Fiel is a distinguished physician and author of numerous published works on various topics relating to pulmonary and critical care medicine. Since 1978, Dr. Fiel has held key hospital appointments including Chief of the Division of Pulmonary / Critical Care Medicine at Drexel University College of Medicine and Hahnemann University in Philadelphia. Dr. Fiel currently serves on the Advisory Board and Speaker’s Bureau with Pfizer, GlaxoSmithKline, Gilead and Novartis. He has been a consultant for GlaxoSmithKline, Novartis, Pfizer, Gilead and Vertex. He has received research grants from the NIH, Cystic Fibrosis Foundation and various pharmaceutical companies.
https://www.linkedin.com/in/stan-fiel-059aa2a7/

Gary Gordon, MD, PhD

Former VP, Oncology Department, AbbVie; CMO, Ayala Pharmaceuticals

An accomplished pharmaceutical executive and strategic business leader with extensive experience in the development of drugs from first in-human studies to approval and commercialization. He brings innovative approaches to the process, leveraging advantageous regulatory pathways and close collaborations with investigators, patient advocacy groups and key academic and government consortiums. Dr. Gordon served as the Vice President, Oncology Department at AbbVie (a spin-off of Abbott), where he oversaw the development of AbbVie’s oncology projects. Dr. Gordon was on the Abbvie-Genentech team that received the 2017 Prix Galien award for the Best Pharmaceutical Product. Dr. Gordon received his undergraduate education at the State University of Stony Brook and his M.D and Ph.D. from The Johns Hopkins University School of Medicine.
https://www.linkedin.com/in/gary-gordon-82753617/.

Craig Granowitz, MD, PhD

Senior VP, Chief Medical Officer, Lexicon Pharmaceuticals

Dr. Granowitz previously served as chief medical officer of Amarin Corporation. Prior to joining Amarin, Dr. Granowitz served as senior vice president and head of global medical affairs, global human health of Merck and in a variety of medical and commercial management positions for Schering‐Plough. Dr. Granowitz received his B.A. from Dartmouth College and his M.D. and Ph.D. from Columbia University.
https://www.linkedin.com/in/craig-granowitz-a43878101/.

Keren Haruvi

President, Sandoz US, Head of North America

Keren Haruvi leads Sandoz’ largest commercial and country organization, the US, and oversees Sandoz commercial operations in Canada. In addition to serving on the Novartis Country Leadership Team, Keren is a member of the Global Sandoz Executive Committee. Prior to joining Sandoz, Keren served as Global Head of M&A at Novartis International AG. Her early career began at Teva. Keren brings 17 years of experience in the pharmaceutical industry marked by success leading major M&A deals, enterprise innovations, and complex market strategies for large-scale, sustainable growth. Keren holds an MBA in Finance from Bar Ilan University and a Bachelor’s degrees in Economics and Chemistry from Tel Aviv University. Nominated for Top 40 Under 40 in The Marker magazine.
https://www.linkedin.com/in/keren-haruvi-snir?trk=people-guest_people_search-card.

Ivan Horak, MD

President of Research & Development, Tessa Therapeutics

President of Research & Development, Tessa Therapeutics. Dr. Horak is responsible for all aspects of Tessa’s research and development, regulatory and clinical development activities. Dr. Horak brings more than 20 years of experience in the global pharmaceutical industry, predominantly focused on oncology drug development, and is a board-certified medical oncologist. He joins Tessa from Symphogen, a clinical-stage antibody company, where he was Head of Global R&D and Chief Scientific and Medical Officer. Prior to that, he was the President of R&D at Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN). Dr. Horak has also held a number of senior research leadership positions in various pharmaceutical companies as well as at the National Cancer Institute (NCI). During his career, Dr. Horak advanced multiple oncology treatments into the clinic and successfully led a number of FDA new drug applications. In addition to publishing over 90 scientific articles and book chapters, Dr. Horak is a member of several prominent medical societies such as the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and European Society of Medical Oncology (ESMO). He also served on the editorial board of the scientific journal, Cancer Research.
https://www.linkedin.com/in/ivan-horak-05468b32/

Michael Ingber, MD

Director, the Center for Specialized Women’s Health

Director, the Center for Specialized Women’s Health at Garden State Urology, within Atlantic Health System. Dr. Ingber’s clinical interests include the treatment of urinary and pelvic disorders. Dr. Ingber has dual board certification in Urology and Female Pelvic Medicine & Reconstructive Surgery and is an Assistant Clinical Professor of Urology at Weill Cornell Medical College. He trained at the world-renowned Cleveland Clinic and has been in practice for more than 13 years.
https://www.linkedin.com/in/michael-ingber-68a50825

Stephen H. Israel

Vice Chairman, Biotechnology & Pharmaceuticals, Korn/Ferry

Stephen Israel is Vice Chairman, Biotechnology and Pharmaceuticals within the Global Life Sciences Practice of Korn Ferry. Mr. Israel is an acknowledged industry expert and consultant to venture-backed and/or emerging high-science biotechnology companies whose leadership requirements are entrepreneurial and largely focused on drug discovery and development. Mr. Israel assists these companies primarily in attracting chief executive officers and board members, but also heads of research and development, heads of business development, chief commercial officers, and chief financial officers.
https://www.linkedin.com/in/stephen-israel-7b883911/

Gilla Kaplan, PhD

Former Director of TB Program, Bill and Melinda Gates Foundation

Dr. Kaplan is an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis (TB). Her work has encompassed developing a deep, holistic understanding of the cellular immune response and how this can be harnessed for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease, exploring novel experimental medicine approaches that harness the immune response for disease control. Gilla joined the Bill and Melinda Gates Foundation (BMGF), first as a member of the Global Health Program Scientific Advisory Committee and subsequently progressing to the position of Director of the TB program for five years. Building on three decades of research experience, at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at UMDNJ (for 10 years), she led the reshaping of the tuberculosis program at BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research.
https://www.linkedin.com/in/gilla-kaplan-1144b236//

Samir Khleif, MD

Biomedical Scholar & Professor of Oncology, Georgetown Uni

Dr. Khleif’s is a pioneer, leading researcher and Key Opinion Leader in the field of immunotherapy. He is a Biomedical Scholar and Professor of Oncology at Georgetown University where he leads the development of a new innovative, high impact immune-oncology program to continue his scientific contribution and translate many of his discoveries into high-impact clinical trials. Dr. Khleif serve on many national and international committees driving the immune-oncology field and he is a scientific advisor for more than 15 immnue-oncology companies. During his tenure at the National Cancer Institute where he served the Chief of the Cancer Vaccine Section, he established one of the first immune therapy and cancer vaccine programs in the field. Dr. Khleif leads an international program to develop cancer care programs in low income countries. Amongst others, Dr. Khleif is the recipient of many national and international awards including the NCI’s Director Golden Star, the NIH Award for Merit, Georgia Distinguished Cancer Scientist and Clinician.
https://www.linkedin.com/in/samir-khleif-4280b29/

Benjamin Maisano

Chief Digital & Innovation Officer, Atlantic Health System

Mr. Maisano is the Chief Digital & Innovation Officer at Atlantic Health System. He is an experienced technologist passionate about creating software solutions that improve healthcare. He previously served as CTO & Head of Application Engineering, Mount Sinai Health System and VP of Engineering at Andera and oFlows, and held lead engineering positions with Bank of NY and UnitedHealth Group.
https://www.linkedin.com/in/benjaminmaisano

Roni Mamluk, PhD

CEO, Ayala Pharmaceuticals

CEO, Ayala Pharmaceuticals. Roni is a senior biopharmaceutical executive with 14 years of experience in drug development companies and background in all aspects of R&D, general management and fundraising. Prior to Ayala Roni was the CEO of Chiasma (NASDAQ: CHMA). She is an inventor of their oral delivery technology, led the development of their lead product through all stages of development, including NDA submission. She was a key player in fundraising for the company including several private financing rounds and led a $70 million crossover financing and a successful IPO of over $100 million in 2015. Roni is now a board member at Chiasma. Prior to that she was heading preclinical development of an oncology product at Adnexus (later acquired by Bristol-Myers Squibb (NYSE:BMY)). She completed her post doc at Children’s Hospital/Harvard Medical School in the field on angiogenesis and received her PhD, summa cum laude, from the Hebrew University in Jerusalem.
https://www.linkedin.com/in/roni-mamluk-0040696/

John Oppenheimer, MD

Director of Clinical Research at Pulmonary, Allergy Associates

Director of Clinical Research at Pulmonary, Allergy Associates & Clinical Professor of Medicine at the New Jersey Medical School. Dr. Oppenheimer is board certified in Internal Medicine and Allergy and Immunology. Dr. Oppenheimer has participated well over 100 clinical studies with over 160 publications and has received numerous awards regarding his contributions in the field of allergy. He serves as both the associate and section editor of the Annals of Allergy Asthma and Immunology, co-section editor of Current Reports of Allergy and Immunology and serves as a reviewer for the Journal of Allergy and Clinical Immunology. He is past chairman of the American Board of Allergy and Immunology, was a member of the PCPI and is an ambassador for the American Board of Medical Specialists.

Daniel Pascheles, Ph.D.

CEO & Partner, Molekule Consulting

CEO & Partner of Molekule Consulting LLC. Former Vice President, Head Global Competitive Intelligence, Merck & Co. Dr. Pascheles joined Merck from Aventis Inc. where he was Vice President and head of Corporate Competitive Intelligence. Dr. Pascheles studied Pharmacy at the Swiss Federal Institute of Technology in Zurich, Switzerland. He received his Ph.D. in Pharmaceutical Technology from the same university.
https://www.linkedin.com/in/daniel-pascheles-06762b1?authType=NAME_SEARCH&authToken=uoxs&locale=en_US&trk=tyah&trkInfo=clickedVertical%3Amynetwork%2CentityType%3AentityHistoryName%2CclickedEntityId%3Amynetwork_4539535%2Cidx%3A0

Alise Reicin, MD

Former President, Global Clinical Development, Celgene

CEO & President of Tectonic Therapeutics. Alice is A C-Suite Executive with extensive early and late stage clinical drug development experience leading to the approval of over 10 novel therapies across a broad range of therapeutic areas. She serves on the board of Homology Therapeutics. Most recently she served as President, Global Clinical Development for Celgene and prior to this she was Head of Global Clinical Development, for EMD Serono. Dr. Reicin had a 19-year career at Merck in which she had leadership roles across a wide variety of therapeutic areas. In her capacity as Vice President, Oncology, she led the Keytruda program and oversaw the initial development and filing activities worldwide, and the initiation of development plans in 7 different indications. Prior to Merck, Dr. Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.
https://www.linkedin.com/in/alise-reicin/

Aran Ron, MD

President, Health Strategies Consultants

President, Health Strategies Consultants; Founder and Chief Medical Officer Oscar Health Plan, Medical Director Pager, Former President, Partners Health Plan and President Chief Operating Officer Group Health inc.; Dr. Ron is a physician executive with more than 25 years of healthcare experience in senior leadership roles in hospitals and health plans, venture capital, benefits management and strategic consulting.
https://www.linkedin.com/in/aranron

Teddy Scott, PhD

CEO, Ethos Cannabis

Dr. Scott is the CEO of Ethos Cannabis, founder and former CEO of PharmaCann. Under his vision and leadership, PharmaCann raised over $185M in capital. In December 2018, PharmaCann entered into an agreement to be acquired by MedMen in a deal valued at $682 million. As a registered patent attorney, Dr. Scott’s practice focused on a wide variety of patent licensing matters and intellectual property issues. Dr. Scott obtained his law degree from Northwestern University with a focus on business law. Dr. Scott obtained his Ph.D. in molecular biophysics from the University of Texas Southwestern Medical Center.
https://www.linkedin.com/in/teddy-scott-ph-d-6763338/

Ken Somberg, MD

Former Chief Medical Officer, TrialSpark, Nevakar, Covance

Dr. Somberg is a pharmaceutical executive with senior leadership experience in global pharma and contract research organizations. He is the former CMO of TrialSpark, Nevakar and Covance with significant prior experience at Novartis Pharmaceuticals as a global therapeutic area head in both Clinical Research (Transplantation and Immunology) and Regulatory Affairs (infectious Diseases, Transplantation and Immunology).
https://www.linkedin.com/in/ken-somberg-4b484612/

Steven Stein, MD

Chief Medical Officer, Incyte Corporation

Steven H. Stein, MD, Chief Medical Officer at Incyte Corporation. Dr. Stein’s primary responsibility is leading all the medical and scientific activities involving clinical development, clinical operations, pharmacovigilance, clinical pharmacology, scientific communications and medical affairs at Incyte. Dr. Stein previously worked at Novartis Oncology as the Senior Vice President and Head of U.S. Clinical Development and Medical Affairs and prior to that at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein earned his MBBCH from the University of Witwatersrand in Johannesburg, South Africa. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the School of Medicine, University of Pennsylvania. Dr. Stein is also an active member of several professional and scientific societies and academic committees.
https://www.linkedin.com/in/steven-stein-58261844/

Yaron Werber, MD, MBA

Managing Director, Senior Biotechnology Analyst, Cowen

Managing Director, Senior Biotechnology Analyst at Cowen; Former Chief Business & Financial Officer, Ovid Therapeutics. Dr. Werber had a 14 year tenure as a highly ranked biotechnology analyst at marquee Wall Street firms. Previously Dr. Werber was a Managing Director at Citi Research, and the Head of the Healthcare and Biotech Equity Research teams. During his career, he has been highly ranked by the Institutional Investor Magazine survey, and has been ranked among the top five analysts in the biotech sector by the “Best on the Street Survey” of the Wall Street Journal.
https://www.linkedin.com/in/yaron-werber/

Partnerships

News

Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial

MISGAV, Israel, June 24, 2024 /PRNewswire/ — Biond Biologics Ltd. (“Biond” or the “Company”), a private clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform for the intracellular delivery of biologics, today announced that the first patient has been dosed in a first-in-human clinical trial testing BND-35, a humanized ILT3/LILRB4 antagonist antibody. The first patient was administered BND-35 as a monotherapy … …

CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations

The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation is investing up to $8.5 million in additional funds in SpliSense to continue clinical trials for its inhaled antisense oligonucleotide (ASO) … …

More news

Contact

Israel Biotech Fund
HaOgen B, 4 Oppenheimer St., 
Rehovot 7670104, Israel

Parking (payable) available at the building.
972-72-2514-175

We would be happy to hear from you
and learn more about your company and
technology. Please feel free to contact us at: [email protected]